2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2016-2-1-17-2371Medicine (miscellaneous)XANTHINE METABOLISM IN THE PROGRESSION OF CHRONIC HEART FAILURE: FEATURES OF DISORDERS IN PATIENTS WITH CONCOMITANT CHRONIC KIDNEY DISEASEXANTHINE METABOLISM IN THE PROGRESSION OF CHRONIC HEART FAILURE: FEATURES OF DISORDERS IN PATIENTS WITH CONCOMITANT CHRONIC KIDNEY DISEASEKolomiietsMaryna V.KolomiietsMaryna V.kolomiec.mv@mail.ruBilchenkoAlexander V.BilchenkoAlexander V.bilchenko.post@gmail.com20162100

The article presents some data of the xanthine metabolism violations study in patients with chronic heart failure and concomitant chronic kidney disease at different stages. The study demonstrates a significant increase in xanthine oxidase activity, that confirms changes of metabolism towards oxidase pathway of uric acid in patients with chronic heart failure with concomitant chronic kidney disease. The negative impact of xanthine metabolism violations on the clinical course and progression of heart failure functional class was demonstrated. Thus in patients with CHF and CKD the progression of functional class and decrease in the left ventricular ejection fraction was associated with increased xanthine oxidase activity, while in patients without concomitant CKD it was associated only with increased serum uric acid levels. The obtained results also show the important role of xanthine oxidase system in the impaired kidney function.

The article presents some data of the xanthine metabolism violations study in patients with chronic heart failure and concomitant chronic kidney disease at different stages. The study demonstrates a significant increase in xanthine oxidase activity, that confirms changes of metabolism towards oxidase pathway of uric acid in patients with chronic heart failure with concomitant chronic kidney disease. The negative impact of xanthine metabolism violations on the clinical course and progression of heart failure functional class was demonstrated. Thus in patients with CHF and CKD the progression of functional class and decrease in the left ventricular ejection fraction was associated with increased xanthine oxidase activity, while in patients without concomitant CKD it was associated only with increased serum uric acid levels. The obtained results also show the important role of xanthine oxidase system in the impaired kidney function.

xanthine oxidasechronic heart failurechronic kidney diseasehyperuricemiaxanthine oxidasechronic heart failurechronic kidney diseasehyperuricemiaСписок литературыDoehner W. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options // Semin Nephrol. 2011. №31(5). Pp. 433–440;Filiopoulos V. New insights into uric acid effects on the progression and prognosis of chronic kidney disease // Ren Fail. 2012. № 34(4). Pp. 510–520;Filippatos G.S. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data / G.S. Filippatos, M.I. Ahmed, J.D. Gladden [et al.] // Eur. Heart. J. 2011. № 32(6). Pp. 712–720;Goicoechea M. Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial / M. Goicoechea, S. Garcia de Vinuesa, U. Verdalles [et al.] // Am J Kidney Dis. 2015. № 65(4). Pp. 543–549;Huang H. Uric acid and risk of heart failure: a systematic review and meta-analysis / H. Huang, B. Huang, Y. Li [et al.] // Eur J Heart Fail. 2014. Jan;16(1). Pp. 15–24;Johnson R.J. Uric acid and chronic kidney disease: which is chasing which? / R.J. Johnson, T. Nakagawa, D. Jalal [et al.] // Nephrol Dial Transplant. 2013. Sep;28(9). Pp. 2221-2228;Kaufman M. Uric acid in heart failure: a biomarker or therapeutic target? // Heart Fail Rev. 2013. Mar;18(2). Pp. 177-186;Madero M. Uric acid and long-term outcomes in CKD / M. Madero, M.J. Sarnak, X. Wang [et al.] // Am J Kidney Dis. 2009. №53(5). Pp. 796–803;Nashar K. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? // Adv Chronic Kidney Dis. 2012. Nov;19(6). Pp. 386-391;Neri L. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider / L. Neri, L.A. Rocca Rey, K.L. Lentine [et al.] // Am J Kidney Dis. 2011. Sep; 58(3). Pp. 398–408;Sturm G. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? (The Mild to Moderate Kidney Disease (MMKD) Study) / G. Sturm, B. Kollerits, U. Neyer [et al.] // Exp Gerontol. 2008. № 43(4). Pp. 347–352;Vaduganathan M. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial) / M. Vaduganathan, S.J. Greene, A.P. Ambrosy [et al.] // Am J Cardiol. 2014. Dec 1; 114 (11).- Pp. 1713-1721.